S&P Futures
4,413.50-1.50(-0.03%)Dow Futures
34,975.00-23.00(-0.07%)Nasdaq Futures
15,064.25+18.00(+0.12%)Russell 2000 Futures
2,217.60-1.80(-0.08%)Crude Oil
70.63+0.07(+0.10%)Gold
1,817.60+3.50(+0.19%)
Cytokinetics, Incorporated (CYTK)
Chart Events
Performance Outlook
| Previous Close | 28.77 |
| Open | 28.83 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1300 |
| Day's Range | 28.24 - 29.22 |
| 52 Week Range | 14.71 - 31.41 |
| Volume | 1,534,674 |
| Avg. Volume | 1,830,022 |
| Market Cap | 2.068B |
| Beta (5Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.00 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.64 |
- GlobeNewswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,750 shares of common stock to 15 new employees, whose employment commenced in July 2021, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.68 per share, which is equal to the closing price of the Company’s common stock on July 3
- GlobeNewswire
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS and Patients Who Previously Participated in Cytokinetics Sponsored ALS Trials SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSF
- Zacks
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
